Related Experiment Video

Updated: Mar 29, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Current Treatment Options in Patients with Hepatitis C Virus Genotype 6

Nghia H Nguyen1, Mindie H Nguyen2

  • 1School of Medicine, University of California, San Diego, La Jolla, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.

Gastroenterology Clinics of North America
|November 25, 2015
PubMed

Insights

Hepatitis C virus (HCV) genotype 6 is common in Southeast Asia, yet most direct-acting antiviral (DAA) data comes from Western studies. New DAA combinations show promise for treating HCV-6, moving beyond older interferon therapies.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis C virus (HCV) infection affects approximately 3% of the global population.
  • HCV prevalence is significantly higher in Southeast Asia (6-7%) compared to the United States (1.8%).
  • Hepatitis C virus genotype 6 (HCV-6) is prevalent in Southeast Asian populations, but underrepresented in clinical trial data.

Purpose of the Study:

  • To review emerging data on direct-acting antiviral (DAA) combinations for HCV genotype 6.
  • To compare the efficacy of new DAA treatments with the current standard of care for HCV-6.

Main Methods:

  • Review of emerging clinical trial data for DAA combinations targeting HCV genotype 6.
  • Analysis of treatment outcomes for HCV-6 patients receiving DAA therapies versus pegylated interferon and ribavirin.

Main Results:

  • Most existing DAA data originates from Western clinical trials where HCV-6 is rare.
  • Pegylated interferon and ribavirin remain the standard of care for HCV-6.
  • Preliminary data suggests efficacy for several DAA combinations in treating HCV-6.

Conclusions:

  • Further research and clinical trials are needed to establish optimal DAA regimens for HCV genotype 6.
  • DAA combinations represent a potential future treatment standard for HCV-6, particularly in endemic regions.
  • Addressing the data gap in DAA efficacy for HCV-6 is crucial for improving patient outcomes in Southeast Asia.

Keywords:
Direct-acting agentsGenotype 6Hepatitis CSVRTreatment

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.3K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620